Accelerate Diagnostics Schedules Call to Review Second Quarter 2017 Results for August 3rd
July 18 2017 - 5:38PM
Accelerate Diagnostics, Inc. announced today it will host a
conference call on Thursday, August 3, 2017 to discuss its second
quarter 2017 financial results and commercial progress.
President and Chief Executive Officer, Lawrence Mehren, joined
by Steve Reichling, Chief Financial Officer, will review financial
results at 4:15 p.m. ET.
Conference Call
To participate in the conference call, dial +1.877.883.0383 and
enter the conference ID: 8021823.
International participants may dial +1.412.902.6506. Please dial
in 10-15 minutes prior to the start of the conference. A replay of
the call will be available by telephone at +1.877.344.7529 (U.S.)
or +1.412.317.0088 (international) using access code 10108001 until
August 17, 2017.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro
diagnostics company dedicated to providing solutions for the global
challenge of antibiotic resistance and healthcare-associated
infections. The company recently obtained FDA marketing
authorization for antimicrobial susceptibility testing direct from
positive blood culture samples using its Accelerate Pheno™ system
and Accelerate PhenoTest™ BC kit. The system and kit leverage
proprietary molecular identification methods and morphokinetic
cellular analysis (MCA) to provide minimum inhibitory
concentrations for a range of applicable antibiotics. The
fully-automated system is designed to eliminate the lengthy culture
and sample preparation steps required prior to antimicrobial
susceptibility testing. Recent market studies suggest the solution
offers results 1-2 days faster than conventional methods, enabling
clinicians to optimize antibiotic selection, dosage, and infusion
strategy specific to the individual patient and their
infection.
The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and
“ACCELERATE PHENOTEST” and diamond shaped logos and marks are
trademarks or registered trademarks of Accelerate Diagnostics,
Inc.
For more information about the company, its products or
technology, visit axdx.com.
Forward-Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, about our projections as to
when certain key business milestones may be achieved, the potential
of our products or technology, the growth of the market, our
estimates as to the size of our market opportunity and potential
pricing, our competitive position and estimates of time reduction
to results, and our future development plans and growth strategy.
Actual results or developments may differ materially from those
projected or implied in these forward-looking statements.
Information about the risks and uncertainties faced
by Accelerate Diagnostics is contained in the section
captioned "Risk Factors" in the company's most recent Annual Report
on Form 10-K, filed with the Securities and Exchange
Commission on February 28, 2017, and in any other reports
that we file with the Securities and Exchange
Commission from time to time. The company's forward-looking
statements could be affected by general industry and market
conditions. Except as required by federal securities laws, the
company undertakes no obligation to update or revise these
forward-looking statements to reflect new events, uncertainties or
other contingencies.
Investors May Contact:
Laura Pierson, Accelerate Diagnostics, +1 520 365-3100, investors@axdx.com
Reporters May Contact:
Andrew Chasteen, Accelerate Diagnostics, +1 520 365-3100, achasteen@axdx.com
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Apr 2023 to Apr 2024